Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
49.6M
-
Number of holders
-
20
-
Total 13F shares, excl. options
-
4.03M
-
Shares change
-
-1.23M
-
Total reported value, excl. options
-
$5.92M
-
Value change
-
-$1.2M
-
Number of buys
-
9
-
Number of sells
-
-7
-
Price
-
$1.47
Significant Holders of Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) as of Q4 2023
22 filings reported holding CADL - Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q4 2023.
Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) has 20 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.03M shares
of 49.6M outstanding shares and own 8.12% of the company stock.
Largest 10 shareholders include Northpond Ventures, LLC (1.94M shares), Sands Capital Ventures, LLC (812K shares), VANGUARD GROUP INC (426K shares), FMR LLC (298K shares), GEODE CAPITAL MANAGEMENT, LLC (139K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (133K shares), Baystate Wealth Management LLC (76.9K shares), BlackRock Inc. (49.3K shares), OneDigital Investment Advisors LLC (29.8K shares), and STATE STREET CORP (27.6K shares).
This table shows the top 20 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.